Skip to main content
. 2023 Nov 9;18(11):e0293666. doi: 10.1371/journal.pone.0293666

Fig 1. Workflow of the active inhibition using luteolin and ferulic acid in GBM and other neurodiseases and the future prospects (Created with Adobe Illustrator and BioRender.com).

Fig 1